**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 80793

**Manuscript Type:** REVIEW

**Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C**

Brzdęk M *et al*. Decade of DAA HCV treatment

Michał Brzdęk, Dorota Zarębska-Michaluk, Federica Invernizzi, Marta Cilla, Krystyna Dobrowolska, Robert Flisiak

**Michał Brzdęk, Krystyna Dobrowolska,** Collegium Medicum, Jan Kochanowski University, Kielce 25-516, Poland

**Dorota Zarębska-Michaluk,** Department of Infectious Diseases, Jan Kochanowski University, Kielce 25-516, Poland

**Federica Invernizzi, Marta Cilla,** Center for Liver Disease, Division of Internal Medicine and Hepatology, IRCCS Ospedale San Raffaele, Milan 20-132, Italy

**Robert Flisiak,** Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok 15-540, Poland

**Author contributions:** Brzdęk M designed the manuscript, carried out the literature review, drafted the manuscript and prepared the tables; Zarębska-Michaluk D designed the manuscript and carried out the literature review; Dobrowolska K approved the final version of the manuscript and prepared the manuscript for submission; Flisiak R designed the manuscript; Zarębska-Michaluk D, Invernizzi F, Cilla M and Flisiak R edited and approved the final version of the manuscript.

**Corresponding author: Dorota Zarębska-Michaluk, PhD, Professor,** Department of Infectious Diseases, Jan Kochanowski University, Radiowa 7, Kielce 25-516, Poland. dorota1010@tlen.pl

**Received:** October 12, 2022

**Revised:** November 22, 2022

**Accepted:** January 9, 2023

**Published online:**

**Abstract**

Chronic infection with the hepatitis C virus (HCV) remains a major health problem affecting approximately 58 million people worldwide. In the era of interferon (IFN)-based regimens, patients particularly infected with genotypes 1 and 4 achieved a low response rate. The implementation of direct-acting antivirals changed the landscape of HCV treatment. The increase in effectiveness provided us with the hope of eliminating HCV as a significant public threat by 2030. In the following years, there was an observed improvement in the treatment of HCV with genotype-specific regimens and highly effective pangenotypic options that are the most recent stage of the revolution. The optimization of therapy was accompanied by changes in the patient profile from the beginning of the IFN-free era over time. Patients treated with antiviral therapies were younger in successive periods, less burdened with comorbidities and comedications, more frequently treatment-naïve and had less advanced liver disease. Before the IFN-free era, specific subpopulations such as patients with HCV/HIV coinfection, those with a history of previous treatment, patients with renal impairment or with cirrhosis had lower chances for a virologic response. Currently, these populations should no longer be considered difficult to treat. Despite the high effectiveness of HCV therapy, there is a small percentage of patients with treatment failure. However, they can be effectively retreated with pangenotypic rescue regimens.

**Key Words:** Hepatitis C virus; Interferon; Direct-acting antiviral; Epidemiology; Chronic hepatitis C

Brzdęk M, Zarębska-Michaluk D, Invernizzi F, Cilla M, Dobrowolska K, Flisiak R. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. *World J Gastroenterol* 2023; In press

**Core Tip:** A decade ago direct-acting antiviral drugs were introduced and have greatly improved the effectiveness of treatment for patients with hepatitis C virus infection. The new drugs have increased the chances of eliminating hepatitis C virus infection as a significant public threat. This paper described changes in the therapeutic options administered over the past decade and documented the changing patient profile over the years in the interferon-free era. Special populations of difficult-to-treat patients in the interferon era currently not meeting this definition are highlighted.

**INTRODUCTION**

Chronic infection with hepatitis C virus (HCV) is one of the leading causes of liver disease in the world. According to the most recent estimates from the World Health Organization (WHO), 58 million people are living with chronic hepatitis C (CHC) worldwide, with the annual number of new infections reaching 1.5 million[1]. About 20% of them are at risk of developing liver cirrhosis, eventually leading to organ failure and hepatocellular carcinoma[2]. These most severe complications of the disease are the cause of death of approximately 290000 people a year. There is no effective vaccine against HCV, but currently available direct-acting antivirals (DAA) can cure more than 95% of people infected with hepatitis C regardless of the genotype (GT).

To date, six major HCV GTs have been identified that differ in more than 35% of the genome sequence[3]. The most common of these worldwide is GT1, considered the most difficult to treat in the era of interferon (IFN)-based therapies. However, this was the first GT in which very high efficacy was achieved with GT-specific therapies at the beginning of the DAA era[4]. Further evolution of antiviral therapy has led to the availability of regimens that are highly effective in infection with any HCV GT and at any stage of liver disease, including decompensated liver cirrhosis[5]. In addition to increased efficacy, safety parameters have improved, and antiviral therapy has become shorter and now lasts 8 or 12 wk in the vast majority of patients[6]. There was also a simplification of regimens by dropping the addition of ribavirin (RBV), which also translated into improved tolerability. Optimization of antiviral therapy has set the groundwork for achieving the WHO’s goal of eliminating HCV infection as a public health threat by 2030. The goal to realize this target remains the diagnosis of infection in patients who are unaware of it.

**CHANGES IN THERAPEUTIC REGIMENS**

***IFN-based therapy***

**Regimens without DAA:** The era of IFN in the treatment of HCV infection began in 1986, even before the identification of the virus, which was then known as non-A, non-B hepatitis virus. Hoofnagle *et al*[7] documented a reduction in transaminase activity as a result of IFNα2b therapy. Despite the beneficial effect of reducing disease activity, the initial responses to treatment were transient[8]. In subsequent years, other investigators reported that the decline was related to viral clearance or a decrease in serum HCV RNA[9]. Sustained virological response (SVR) after 24-wk monotherapy with recombinant IFN ranged from 3%-6%, and IFN administered for 48 wk resulted in 13%-19% efficacy[10,11]. Adding RBV to IFN improved treatment efficacy to about 40%[10–13].

The next milestone in the antiviral treatment was the introduction of two forms of long-acting pegylated IFN (pegIFN), alfa-2a and alfa-2b, which were used once a week. This change was one of the key elements in improving treatment adherence and greater efficacy of antiviral therapy[14,15]. In randomized multicenter trials, the SVR rate with pegIFN monotherapy ranged from 15% to 39%[16,17], and the addition of RBV to the regimen increased efficacy to about 50%[15,18]. HCV GTs has been identified as the most important independent predictor of response to pegIFN + RBV treatment.

The prospective PROPHESYS study involving 7163 patients treated with pegIFN + RBV for 48 wk showed better efficacy rates of 71.4% and 60.6% in patients with GT2 and GT3 infections, respectively, compared to patients with GT1 (41.8%) and GT4 (41%) infections. The higher efficacy of therapy was also observed in patients without advanced liver fibrosis or cirrhosis[19]. The most important predictor of response to therapy regardless of HCV GT was undetectable HCV RNA at week 4 of therapy, defined as the rapid virological response as proven by a retrospective study involving 1383 patients[20]. These findings allowed the reduction of the length of treatment to less than 24 wk in GT2- and GT3-infected patients who achieved rapid virological response without a significant decrease in efficacy compared to those with detectable HCV RNA after 4 wk of treatment who required treatment for 24 wk[21]. In addition to virologic response at week 4, treatment length was determined by the response at week 12; GT1-infected patients with detectable serum HCV RNA after 12 wk of treatment benefited from extending treatment to 72 wk[22,23].

The efficacy of IFN-containing regimens was limited by safety issues; adverse events of therapy were frequent and led to treatment discontinuation in 5%-16% of cases[15,24]. Fatigue, headache, fever, malaise, myalgia, neutropenia and thrombocytopenia were reported as the most common adverse events[25]. The main side effect associated with RBV use resulting in its dose reduction in 20% of patients was hemolytic anemia[18].

**Regimens with DAA:** The introduction of the protease inhibitors telaprevir (TVR) and boceprevir in 2011 launched the era of the first DAAs for the treatment of HCV infection[26,27]. Initially, the new drugs were registered for use with pegIFN + RBV only in patients with GT1 infection. Cure rates following triple therapy increased to about 70% compared to previously used regimens containing only pegIFN + RBV[28]. Results from the randomized, double-blind, placebo-controlled ADVANCE trial evaluating a triple regimen with TVR in treatment-naïve GT1-infected patients showed that therapy could be shortened to 24 wk in most without reducing efficacy[29].

Among patients after previous treatment failure assessed in the randomized phase 3 REALIZE trial, patients with prior relapse achieved SVR rates of 83%-88% following treatment with pegIFN + RBV + TVR, while this was only 30% for null responders[30].

The most difficult population to treat with a triple regimen containing first-generation protease inhibitors, TVR or boceprevir, was the population of treatment-experienced patients with liver cirrhosis due to very low efficacy and a poor safety profile[31–33].

Registration of new DAAs has broadened the spectrum of clinical use of triple-drug regimens. The protease inhibitor simeprevir and the non-structural protein 5A (NS5A) inhibitor daclatasvir (DCV) combined with pegIFN + RBV could be used in GT1-infected patients and those with GT4 infection with an SVR rate exceeding 82% in treatment-naïve patients[34–36]. The addition of the polymerase inhibitor, sofosbuvir (SOF) to pegIFN + RBV enabled triple therapy for patients infected with any HCV GT[37,38].

***IFN-free regimens***

**GT-specific options:** Although triple-drug therapies have resulted in higher SVR rates compared to pegIFN + RBV treatment, there is still a major limitation related to side effects as well as contraindications to therapy when using IFN. Patients with liver cirrhosis and hematologic disorders as well as those with decompensated liver disease or severe diseases of other organs and systems were left out of treatment. These safety issues were overcome by the introduction of IFN-free therapies. These well-tolerated and highly effective regimens revolutionized the antiviral therapy of CHC[39]. The first registered DAA that could be used without IFN was SOF[37]. The combination of this drug with the inhibitor of HCV NS5A protein, ledipasvir (LDV), administered with or without RBV resulted in a GT-specific combination active against GT1 and 4 infections.

Randomized, open-label phase 3 trials, ION-1 and ION-2, documented 95%-100% efficacy in GT1-infected patients depending on treatment duration (12 or 24 wk), prior treatment history and RBV use. However, lower efficacy was observed in treatment-experienced patients with liver cirrhosis[40,41] (Table 1). The ION-3 study demonstrated that in treatment-naïve patients without liver cirrhosis even shortening SOF/LDV ± RBV therapy to 8 wk does not significantly affect efficacy[42].

The results of a retrospective real-world evidence (RWE) study conducted in a large cohort of patients in the United States confirmed the high effectiveness of this regimen with 93% of GT1-infected patients responding in 93% (*n* = 9912), while the cure rate in GT4-infected patients was 87% (*n* = 97)[43].

Another GT-specific option registered for patients with compensated liver disease was the combination of ombitasvir (OBV), an inhibitor of NS5A, and ritonavir-boosted paritaprevir (PTV/r), an HCV protease inhibitor. In cases of infection with GT4, it was used with RBV for 12 wk, while for GT1-infected patients the addition of a third DAA, dasabuvir (DSV), acting as a polymerase inhibitor, was obligatory[44]. The addition of RBV and the length of therapy depended on the subtype and the presence of liver cirrhosis.

The phase 3 clinical trials SAPPHIRE-I and SAPPHIRE-II confirmed the efficacy of the 12-wk option of OBV/PTV/r + DSV + RBV at the level of 96% in GT1-infected patients without liver cirrhosis regardless of history of previous therapy[45,46]. Results from the phase 3 PEARL-III and PEARL-IV clinical trials proved that the inclusion of RBV improved efficacy in GT1a-infected patients, while the SVR in GT1b-infected patients exceeds 99% regardless of RBV addition[47].

The findings of the phase 3b study GARNET allowing the shortening of OBV/PTV/r + DSV therapy in GT1b-infected patients without cirrhosis to 8 wk without affecting efficacy formed the basis for updating the label[48]. Patients with GT4 infection both with and without compensated cirrhosis treated with OBV/PTV/r + RBV in the multinational AGATE-I and AGATE-I part II trials and the Egyptian AGATE-II trial achieved high SVR rates of 96%-100%. The demonstration that prolonging therapy did not improve the success rate among patients with compensated cirrhosis became the basis for updating the label, and regardless of the severity of liver disease, GT4-infected patients received a 12-wk treatment course[49–51]. The high effectiveness of the OBV/PTV/r + DSV +/- RBV regimen of 95% to 100% in GT1 and GT4-infected patients regardless of the severity of liver disease[52-54] and history of prior antiviral treatment has been confirmed in numerous real-world studies[55–57].

Another GT-specific DAA regimen designed for patients with GT1 and GT4 infection without cirrhosis and with compensated cirrhosis includes combinations of the protease inhibitor, grazoprevir (GZR), and the NS5A inhibitor, elbasvir (EBR), used for 12 wk. The option to add RBV and extend therapy to 16 wk applies to GT1a and GT4-infected patients with an initial viral load > 800000 IU/mL. Efficacy in phase 3 clinical trials in treatment-naïve patients without cirrhosis and those with compensated cirrhosis was 97% and 94%, respectively, while treatment-experienced patients responded in 96.6% and 93.8%, respectively[58,59]. However, it should be emphasized that these are data calculated for intent-to-treat analysis.

**Pangenotypic options:** The first available DAA regimen with activity against all HCV GTs was a combination of SOF and RBV. The efficacy of 12 wk of therapy with SOF + RBV in treatment-naïve patients with GT1-3 infection evaluated in a phase 3 clinical trial was 72% in patients without cirrhosis and 47% in patients with cirrhosis, respectively[60] (Table 2). A higher response rate of 97.1% was documented in patients with GT2 infection. The efficacy of this regimen in treatment-experienced GT2 and GT3-infected patients participating in the phase 3 FUSSION study was 96% *vs* 37% for patients without cirrhosis and 60% *vs* 19% in patients with cirrhosis, respectively[61]. Extending the duration of therapy to 16 wk increased the cure rates to 100% and 62.5% in patients without cirrhosis infected with GT2 *vs* GT3, while patients with liver cirrhosis responded in 62.5% and 61.0%, respectively. A comparison of treatment duration (16 wk *vs* 24 wk) in patients with GT3 infection documented the higher efficacy followed longer therapy with SVR of 86.5% and 78.6% in patients without cirrhosis and those with cirrhosis, respectively[62].

Extending treatment to 24 wk improved the response rate, especially in the GT3-infected treatment-experienced patients with cirrhosis responding in 76%. These values were still unsatisfactory, and the regimen was considered suboptimal in this patient population[62,63,64].

The use of a 12-wk regimen with pangenotypic activity, consisting of SOF and DCV, improved SVR rates in GT3-infected patients without cirrhosis to about 97% in treatment-naïve individuals and 94% in those who failed prior therapy. However, the efficacy reported in patients with cirrhosis was much lower, approximately 63%[65].

A real breakthrough in the treatment of CHC came with the introduction of new pangenotypic options highly effective against all HCV GTs. Based on phase 3 ASTRAL registration studies, in 2016 the Food and Drug Administration approved a combination consisting of SOF and the NS5A inhibitor velpatasvir (VEL) for patients without and with liver cirrhosis, including decompensated individuals[66]. The 12-wk regimen in patients with compensated liver disease resulted in an SVR of 95%-100% regardless of the history of previous therapy, while patients with decompensated liver cirrhosis responded in 84%[67-69]. The extension of therapy to 24 wk in this patient population increased the response rate to 88% and the addition of RBV to 94% in the modified intent-to-treat analysis[69]. The lowest efficacy was achieved in GT3-infected patients, with SVR rates ranging from 50% to 85%, but it should be noted that the number of patients in this study was relatively small, 12-14 in each treatment arm.

The high efficacy of SOF/VEL was confirmed in a meta-analysis of 12 studies from routine clinical practice. Of the 5196 patients with response rate data, 99% achieved SVR[70]. The analysis revealed unfavorable factors associated with a reduction in the odds of virologic response to about 98%, such as GT3 and compensated liver cirrhosis. Importantly, patients with current or prior decompensated cirrhosis were excluded from the analysis. Another new pangenotypic option containing the protease inhibitor glecaprevir (GLE) and the NS5A inhibitor pibrentasvir (PIB) became available for patients with compensated liver disease after approval by Food and Drug Administration in 2017[71].

The efficacy of the 12-wk GLE/PIB regimen in patients with GT 1, 2, 4-6 infection without cirrhosis as well as with compensated cirrhosis participating in phase 3 clinical trials reached 100% and 99%, respectively[72–74]. An equally high efficacy of 99% was reported in GT3-infected patients without liver cirrhosis in the phase 3 ENDURANCE-3 trial[72].

Shortening therapy to 8 wk in patients infected with GT1-6 without cirrhosis evaluated in the SURVEYOR-I and -II phase 2 studies and with compensated cirrhosis participating in the EXPEDITION-8 phase 3 trial did not affect the efficacy of therapy and became the basis for updating the label[75,76]. However, the EudraCT trial showed that further reduction of therapy to 4 wk reduced efficacy to 59% (10/17) for GLE/PIB without RBV and to 73% (11/15) for GLE/PIB + RBV, and drug target-specific substitutions associated with NS5A resistance were identified as a predictor of virologic failure[77].

The registration of the GLE/PIB option for use in GT1-6-infected patients with stage 4 or 5 chronic kidney disease, including those on dialysis, was based on the results of the EXPEDITION-4 trial with a 98% SVR rate in this population of patients[78]. The high efficacy of treatment with the GLE/PIB regimen has been confirmed in everyday clinical practice. A meta-analysis of 18 RWE studies involving 12531 patients documented greater than 95% efficacy regardless of GT, presence of compensated cirrhosis and history of prior therapy[79].

In 2017, a new triple pangenotypic regimen containing SOF/VEL and the HCV protease inhibitor voxilaprevir (VOX) was also registered for patients with compensated liver disease[80]. Despite its high efficacy regardless of the history of previous therapy, in practice it is used primarily as a rescue regimen after the failure of DAA therapy, and it is discussed in detail later in this manuscript, in the section on rescue therapy.

**CHANGES IN THE PROFILE OF HCV-INFECTED PATIENTS OVER TIME**

The availability of safe and effective therapy has led the WHO to set a goal of eliminating HCV as a significant public threat by 2030. This goal was defined as a 65% reduction in mortality and a 90% reduction in new chronic infections compared to 2015[85]. In June 2021, the WHO presented targets to reduce the annual incidence to ≤ 5 per 100000 and annual mortality to ≤ 2 per 100000[86]. In a large model study representing 93% of the global population, the Polaris Observatory HCV Collaborators estimated a reduction in global HCV prevalence from 0.9% (63.6 million) in 2015 to 0.7% (56.8 million) in 2020. During the analysis period, 8.7 million patients worldwide were treated, and significant changes were observed in the demographic and clinical characteristics of HCV-infected patients[87].

Published data indicated that patients treated with antiviral therapy for chronic HCV infection were less burdened by comorbidities and were less likely to use comedications in the subsequent time intervals analyzed[88-91]. A decrease in the median age of treated patients was also observed. Elsharkawy *et al*[88] analyzed the data of 337042 Egyptian patients of the national CHC treatment program who started therapy from October 2014 (the first introduction of IFN-free regimens in Egypt) to March 2016. The population was divided into three-time intervals of 6 mo each. The results showed a reduction in age (mean ± standard deviation) from 53 ± 9 years in the first cohort to 49 ± 12 years in the last group[88,92]. In the Polish cohort of 10152 patients observed between 2015 and 2018, a more pronounced reduction in median age was observed from 58 at the beginning of the analyzed period to 49 at the end[89]. Furthermore, the prevalence of comorbidities and the use of concomitant medications decreased significantly in subsequent time intervals from 68.6% to 59.5% and from 64.6% to 57.7%, respectively[89].

A study carried out in the United States documented a 9.3% increase in the proportion of HCV RNA-positive patients under the age of 50 between 2017 and 2019, while German observations covering the period 2014-2018 demonstrated an increase of 14.7% in this age group of treated patients[90,91].

In 2015, Messina *et al*[3] published a comprehensive study on the prevalence and distribution of GTs worldwide before the IFN-free era. The analysis included 1217 studies published between 1993 and 2013, and they documented GT1 as the most common HCV GT globally (46%), followed by GT3 and GT4 (30% and 9%, respectively). The prevalence of GTs showed geographic variation; the proportion of GT4 in central sub-Saharan Africa accounted for more than 97% of all HCV infections. At the end of 2015, the estimated order of GTs remained the same, with GT1 and GT3 being the dominant GTs worldwide at 44% and 25% prevalence, respectively, and GT4 continuing to rank third with a 15% prevalence[93]. Given the high efficacy of pangenotypic regimens, the need for genotyping seems to be losing ground[94], and to the best of our knowledge, no studies have been published in the last few years on the prevalence and distribution of GTs at the global level.

However, several papers have analyzed this issue in patient populations at the national level. Studies of Polish and German cohorts have shown a high proportion of GT1-infected patients among antiviral-treated patients at the beginning of the DAA era[89,95]. Over time, the proportion of these patients has declined in favor of GT3-infected patients. The explanation for this phenomenon is related to the changes in therapeutic regimens discussed above. At the beginning of the DAA era, GT1-infected patients had access to highly effective GT-specific regimens, while for patients with GT3 infection there was only one IFN-free option, the 24-wk SOF + RBV combination. Because of the suboptimal virologic response achieved with this regimen, many GT3-infected patients, especially those with non-advanced liver disease, preferred the shorter 12-wk triple-drug treatment of SOF + pegIFN + RBV or waiting for more effective IFN-free options[63]. Another IFN-free therapeutic option that was more effective in patients with GT3 infection, the SOF + DCV + RBV combination, was not widely available in many countries since it contained drugs from different manufacturers, and this made registration and reimbursement difficult.

Thus the prevalence of GT1-infected DAA-treated patients decreased by 9% in Poland between 2015 and 2018 and 12% in Germany between 2014 and 2019. A similar trend was observed among 76110 patients after the introduction of DAA regimens in China, with the percentage of GT3-infected patients increasing by almost 6% between 2016 and 2020[96].

At the beginning of the IFN-free era, the proportion of patients with advanced fibrosis and cirrhosis was significantly higher compared to subsequent years, likely related to priority access to reimbursable DAA options in this patient population[97]. A single-center RWE study of Polish patients documented that the percentage of patients on antiviral therapy who were diagnosed with cirrhosis decreased significantly from 51% in 2015-2016 to 11.8% in 2018[98].

**SPECIFIC SUBPOPULATIONS OF HCV-INFECTED PATIENTS**

In the era of IFN-based antiviral therapies, specific subpopulations of patients were identified and recognized as difficult to treat because of more prevalent contraindications to therapy, poorer adherence, more frequent adverse events with associated treatment discontinuation and lower efficacy[4,25]. In the era of DAA therapy, these populations are essentially no longer difficult to treat, although some researchers have noted factors that negatively affect the success of therapy, especially if they occur together.

***Patients with HCV/HIV coinfection***

The prevalence of HCV/HIV coinfection varies significantly across subpopulations and geographic regions. Recent estimates have shown that about 2.5% of HIV-infected patients are coinfected with HCV[99]. In the era of IFN-based regimens, HIV/HCV coinfected patients were considered more challenging compared to those with HCV monoinfection. Inferior adherence, lower SVR rates, drug interactions and unfavorable safety profiles were significant therapeutic concerns[100]. DAA therapy has revolutionized the treatment of HIV/HCV-coinfected individuals, improving adherence, efficacy and safety profile. Clinical trials using a range of DAA options have shown high rates of SVR exceeding 95% and comparable to efficacy in patients with HCV monoinfection regardless of the type of regimen used[101-104]. Similar high effectiveness has been observed in studies carried out in routine medical practice, although some authors have reported lower response rates to DAA therapy in populations with HIV coinfection than in populations with HCV monoinfection[105-109].

***Treatment-experienced patients***

Similar observations apply to patients with a history of prior failed therapy. Numerous clinical trials with different DAA options do not document the lower SVR rates as compared to treatment-naïve patients, while in some RWE studies this parameter has been identified as an unfavorable factor in the chances of virologic response with lower SVR rates ranging from 0.7% to 2.4% depending on the regimen used, type of GT and severity of liver disease[39,55,70,73,110].

A distinct category of treatment-experienced patients is those who have not responded to IFN-free options subjected to subsequent DAA therapy. Data from the German hepatitis C registry described an unsatisfactory 79.5% response rate in patients retreated with DAA after the failure of initial IFN-free treatment[111]. These results were supported by findings from a Polish RWE study reporting effectiveness of 86% with GT-specific DAA retreatment in previous IFN-free nonresponders[112]. A newly published analysis also from Poland evaluated patients who failed pangenotypic therapy and underwent pangenotypic retreatment[113].

***Patients with renal impairment***

Chronic infection with HCV may be an independent risk factor for the development or progression of chronic kidney disease (CKD)[114]. On the other hand, due to suboptimal hygiene measures in some dialysis units, the prevalence of HCV infection in hemodialysis patients was significantly higher (3.8%-31.1%)[115]. Historically, the use of IFN + RBV therapy in patients with renal failure has been limited due to contraindications to both medications[116]. Also, the efficacy of the IFN-based regimen in this patient population was lower and the safety profile was inferior compared to patients with normal renal function. Hemodialyzed patients with CHC treated with pegIFN analyzed in a meta-analysis of 24 clinical trials achieved an SVR rate of 40%, while 14% of them discontinued treatment due to adverse events[117]. Due to the distinct metabolic pathways of DAAs, their introduction to treatment has offered an effective and well-tolerated therapy for patients with renal impairment, including hemodialysis patients with HCV infection[118].

SOF-containing regimens are approved for use in patients with estimated glomerular filtration rate > 30 mL/min/1.73 m2 due to limited safety data in patients with severe renal impairment. However, since 2019 according to the label, these combinations can also be administered with no dose adjustment at lower estimated glomerular filtration rate values and in patients requiring hemodialysis if no other relevant treatment options are available[94,119,120]. The meta-analysis included 21 studies with 717 patients in CKD stages 4-5, demonstrating an SVR of 97% and a good safety profile of SOF-containing regimens[121]. Therapy should be used with caution, and renal parameters should be carefully monitored during the treatment course due to the possibility of worsening renal function, as demonstrated by Saxena *et al*[122].

Among GT-specific options, the OBV/PTV/r +/- DSV and GZR/EBR regimens are registered for use in patients with renal failure, including those on dialysis[44,123]. The RUBY-1 and RUBY-2 clinical trials demonstrated an SVR of 95% in HCV-infected patients in CKD stage 4-5 treated with OBV/PTV/r +/- DSV +/- RBV, while the therapy with GZR/EBR in this patient population evaluated in C-SURFER study resulted in 99% efficacy[124,125]. Of the pangenotypic options, the GLE/PIB regimen has been registered for patients with severe renal failure, including those on dialysis; the good safety profile and high efficacy of this combination were documented in clinical trials[78,126].

***Patients with compensated liver cirrhosis***

The efficacy achieved in compensated liver patients with cirrhosis treated with GT-specific options ranged from 92% to 96%, while clinical trials evaluating pangenotypic regimens in this patient population showed an SVR of 96% and above[67,76,127,128]. Although these results corresponded with high treatment efficacy, they were lower compared to SVR in patients without cirrhosis[67,76,129]. Data from the RWE study confirmed the worse effects of therapy in the population with cirrhosis than in patients without cirrhosis. Moreover, decompensation of liver function was identified as an independent negative predictor of SVR[69,110,130]. It should be noted that IFN-based therapies were absolutely contraindicated in patients with decompensated cirrhosis due to the side effects of this cytokine[131]. Also, not all DAA regimens are registered for use in this patient population. Combinations containing protease inhibitors are not recommended because of the risk of worsening liver function[94]. Among GT-specific regimens, the SOF/LDV option is approved for use in patients with decompensated cirrhosis. Among pangenotypic regimens, it applies to SOF ± DCV ± RBV and SOF/VEL combinations[132-134].

***Other factors affecting treatment outcome***

Male sex is recognized as a factor that may reduce the effectiveness of DAA therapy. Multivariate logistic regression models performed in a large retrospective analysis of 17487 United States veterans with HCV infection found that the male sex was an independent negative predictor of achieving SVR[43]. These data confirm the results of other RWE analyses conducted in numerically smaller populations[110,135].

Patients with GT3 infection, who were considered an easy-to-treat population in the era of IFN-based therapy, are less likely to respond to treatment in the era of DAAs[43,136,137].

**RESCUE REGIMENS**

Despite the very high efficacy of currently available DAA therapy exceeding 95%, there is still a small proportion of patients who do not respond to treatment, especially when different negative predictors of achieving SVR are present[113,138]. Failure of therapy with DAA regimens could be related to the selection of mutant-resistant strains carrying resistance-associated substitutions, and those contributing lower sensitivity to NS5A inhibitors are the most persistent[139]. The only therapeutic option registered for treatment in such cases is a three-drug pangenotypic combination of SOF/VEL/VOX. The introduction of this regimen improved the SVR rates to 96%-98% in patients after the failure of DAA therapy evaluated in POLARIS-1 and POLARIS-4 clinical trials[84,80]. The findings from registration studies are supported by data from routine medical practice[113,140,141]. A meta-analysis of 10 cohorts including 1187 patients demonstrated that 96% of them achieved undetectable HCV RNA 12 wk after the end of treatment. However, lower effectiveness was reported for those with GT3 infection and cirrhosis[140,141].

According to the most recent European Association for the Study of the Liver and American Association for the Study of Liver Diseases guidelines, in patients who have failed SOF/VEL/VOX, extended retherapy with this regimen plus weight-based RBV or a combination of GLE/PIB + SOF + RBV is recommended, although no data from clinical trials for SOF/VEL/VOX nonresponders are available[94,142]. It was pointed out that retreatment can be optimized based on resistance-associated substitution testing[94]. A 96% efficacy of the rescue regimen of GLE/PIB in combination with SOF and RBV was evaluated in the MAGELLAN-3 clinical trial, but all 23 included participants were GLE/PIB failures[143].

Very limited data on patients receiving GLE/PIB + SOF +/- RBV retherapy are available from RWE studies. In an open-label study conducted in New Zealand, patients treated with GLE/PIB + SOF after prior DAA failure achieved a virologic rate of 98%[144].

**CONCLUSION**

Since the beginning of the availability of IFN-free options, we have observed changes occurring in the regimens used from GT-specific to highly potent pangenotypic options, including rescue combinations. These are accompanied by changes in the profile of the HCV-infected population, with patients starting treatment over time being younger, with less advanced liver disease and less burdened by comorbidities. Despite the very high effectiveness of current DAA options, some factors including male sex, GT3 infection, liver cirrhosis and prior failure of DAA therapy are still identified that lower the chances of a cure.

**REFERENCES**

1 **World Health Organization.** Fact-sheets on Hepatitis C. 2022 Jun 24 [cited 4 October 2022]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

2 **Lingala S**, Ghany MG. Natural History of Hepatitis C. *Gastroenterol Clin North Am* 2015; **44**: 717-734 [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003]

3 **Messina JP**, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*; **61**: 77-87 [PMID: 25069599 DOI: 10.1002/hep.27259]

4 **Flisiak R**, Pogorzelska J, Berak H, Horban A, Orłowska I, Simon K, Tuchendler E, Madej G, Piekarska A, Jabłkowski M, Deroń Z, Mazur W, Kaczmarczyk M, Janczewska E, Pisula A, Smykał J, Nowak K, Matukiewicz M, Halota W, Wernik J, Sikorska K, Mozer-Lisewska I, Rozpłochowski B, Garlicki A, Tomasiewicz K, Krzowska-Firych J, Baka-Ćwierz B, Kryczka W, Zarębska-Michaluk D, Olszok I, Boroń-Kaczmarska A, Sobala-Szczygieł B, Szlauer B, Korcz-Ondrzejek B, Sieklucki J, Pleśniak R, Ruszała A, Postawa-Kłosińska B, Citko J, Lachowicz-Wawrzyniak A, Musialik J, Jezierska E, Dobracki W, Dobracka B, Hałubiec J, Krygier R, Strokowska A, Chomczyk W, Witczak-Malinowska K. Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study. *Clin Exp Hepatol* 2016; **2**: 138-143 [PMID: 28856278 DOI: 10.5114/ceh.2016.63870]

5 **Alqahtani SA**, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. *Cells* 2021; **10** [PMID: 34831314 DOI: 10.3390/cells10113091]

6 **Zarębska-Michaluk D**. Viral hepatitis C treatment shortening - what is the limit? *Clin Exp Hepatol* 2019; **5**: 265-270 [PMID: 31893236 DOI: 10.5114/ceh.2019.88085]

7 **Hoofnagle JH**, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. *N Engl J Med* 1986; **315**: 1575-1578 [PMID: 3097544 DOI: 10.1056/NEJM198612183152503]

8 **Di Bisceglie AM**, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. *N Engl J Med* 1989; **321**: 1506-1510 [PMID: 2509917 DOI: 10.1056/NEJM198911303212204]

9 **Brillanti S**, Garson JA, Tuke PW, Ring C, Briggs M, Masci C, Miglioli M, Barbara L, Tedder RS. Effect of alpha-interferon therapy on hepatitis C viraemia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study. *J Med Virol* 1991; **34**: 136-141 [PMID: 1716296 DOI: 10.1002/jmv.1890340213]

10 **McHutchison JG**, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; **339**: 1485-1492 [PMID: 9819446 DOI: 10.1056/NEJM199811193392101]

11 **Poynard T**, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 1998; **352**: 1426-1432 [PMID: 9807989 DOI: 10.1016/s0140-6736(98)07124-4]

12 **Reichard O**, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. *Lancet* 1998; **351**: 83-87 [PMID: 9439491 DOI: 10.1016/s0140-6736(97)06088-1]

13 **Dusheiko G**, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. *J Hepatol* 1996; **25**: 591-598 [PMID: 8938532 DOI: 10.1016/s0168-8278(96)80225-x]

14 **McHutchison JG**, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. *Gastroenterology* 2002; **123**: 1061-1069 [PMID: 12360468 DOI: 10.1053/gast.2002.35950]

15 **Manns MP**, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; **358**: 958-965 [PMID: 11583749 DOI: 10.1016/s0140-6736(01)06102-5]

16 **Heathcote EJ**, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. *N Engl J Med* 2000; **343**: 1673-1680 [PMID: 11106716 DOI: 10.1056/NEJM200012073432302]

17 **Zeuzem S**, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med* 2000; **343**: 1666-1672 [PMID: 11106715 DOI: 10.1056/NEJM200012073432301]

18 **Fried MW**, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; **347**: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]

19 **Marcellin P**, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, Jensen D, Lengyel G, Mangia A, Ouzan D, Puoti M, Rodriguez-Torres M, Shiffman ML, Schmitz M, Tatsch F, Rizzetto M. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. *Hepatology* 2012; **56**: 2039-2050 [PMID: 22706730 DOI: 10.1002/hep.25892]

20 **Fried MW**, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. *J Hepatol* 2011; **55**: 69-75 [PMID: 21145856 DOI: 10.1016/j.jhep.2010.10.032]

21 **Mangia A**, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 2005; **352**: 2609-2617 [PMID: 15972867 DOI: 10.1056/NEJMoa042608]

22 **Berg T**, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology* 2006; **130**: 1086-1097 [PMID: 16618403 DOI: 10.1053/j.gastro.2006.02.015]

23 **Katz LH**, Goldvaser H, Gafter-Gvili A, Tur-Kaspa R. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients. *Cochrane Database Syst Rev* 2012: CD008516 [PMID: 22972122 DOI: 10.1002/14651858.CD008516.pub2]

24 **Hadziyannis SJ**, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; **140**: 346-355 [PMID: 14996676 DOI: 10.7326/0003-4819-140-5-200403020-00010]

25 **Fried MW**. Side effects of therapy of hepatitis C and their management. *Hepatology* 2002; **36**: S237-S244 [PMID: 12407599 DOI: 10.1053/jhep.2002.36810]

26 **Bacon BR**, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011; **364**: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]

27 **Sherman KE**, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. *N Engl J Med* 2011; **365**: 1014-1024 [PMID: 21916639 DOI: 10.1056/NEJMoa1014463]

28 **D'Ambrosio R**, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? *Curr Opin Virol* 2017; **24**: 31-37 [PMID: 28419938 DOI: 10.1016/j.coviro.2017.03.017]

29 **Jacobson IM**, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011; **364**: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]

30 **Zeuzem S**, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011; **364**: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]

31 **Colombo M**, Strasser S, Moreno C, Abrao Ferreira P, Urbanek P, Fernández I, Abdurakmonov D, Streinu-Cercel A, Verheyen A, Iraqi W, DeMasi R, Hill A, Lonjon-Domanec I, Wedemeyer H. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. *J Hepatol* 2014; **61**: 976-983 [PMID: 24946280 DOI: 10.1016/j.jhep.2014.06.005]

32 **Zarębska-Michaluk D,** Flisiak R, Janczewska E, Berak H, Dobracka B, Suska-Librant M, Kozielewicz D, Lojewski W, Jurczyk K, Lapinski T, Klosinska-Postawa B, Wróblewski J, Augustyniak K, Dudziak M, Olszok I, Ruszala A, Kryczka W, Pisula A, Horban A, Dobracki W. Effect of pegylated interferon or ribavirin dose reduction during telaprevir based therapy on SVR12 in null-responders and relapsers with advanced liver fibrosis. *J Hepatol (AdvEx study)* 2014; **60**: 474 [DOI: 10.1016/S0168-8278(14)61329-5]

33 **Hézode C**, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. *J Hepatol* 2013; **59**: 434-441 [PMID: 23669289 DOI: 10.1016/j.jhep.2013.04.035]

34 **Moreno C**, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, Zoulim F, Grange JD, Shukla U, Lenz O, Ouwerkerk-Mahadevan S, Fevery B, Peeters M, Beumont M, Jessner W. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. *J Hepatol*2015; **62**: 1047-1055 [PMID: 25596313 DOI: 10.1016/j.jhep.2014.12.031]

35 **Jacobson I**, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. *World J Gastroenterol* 2016; **22**: 3418-3431 [PMID: 27022224 DOI: 10.3748/wjg.v22.i12.3418]

36 **Hézode C**, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, Bourlière M, Thabut D, Molina E, Rustgi V, Samuel D, McPhee F, Liu Z, Yin PD, Hughes E, Treitel M; COMMAND-4 study team. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). *Antivir Ther* 2015; **21**: 195-205 [PMID: 26313445 DOI: 10.3851/IMP2985]

37 **Keating GM**. Sofosbuvir: a review of its use in patients with chronic hepatitis C. *Drugs* 2014; **74**: 1127-1146 [PMID: 24958336 DOI: 10.1007/s40265-014-0247-z]

38 **Elsharkawy A**, Fouad R, El Akel W, El Raziky M, Hassany M, Shiha G, Said M, Motawea I, El Demerdash T, Seif S, Gaballah A, El Shazly Y, Makhlouf MA, Waked I, Abdelaziz AO, Yosry A, El Serafy M, Thursz M, Doss W, Esmat G. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. *Aliment Pharmacol Ther* 2017; **45**: 681-687 [PMID: 28070899 DOI: 10.1111/apt.13923]

39 **Spengler U**. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. *Pharmacol Ther* 2018; **183**: 118-126 [PMID: 29024739 DOI: 10.1016/j.pharmthera.2017.10.009]

40 **Afdhal N**, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. *N Engl J Med* 2014; **370**: 1889-1898 [PMID: 24725239 DOI: 10.1056/NEJMoa1402454]

41 **Afdhal N**, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. *N Engl J Med* 2014; **370**: 1483-1493 [PMID: 24725238 DOI: 10.1056/NEJMoa1316366]

42 **Kowdley KV**, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. *N Engl J Med* 2014; **370**: 1879-1888 [PMID: 24720702 DOI: 10.1056/NEJMoa1402355]

43 **Ioannou GN**, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, Su F, Berry K. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. *Gastroenterology* 2016; **151**: 457-471.e5 [PMID: 27267053 DOI: 10.1053/j.gastro.2016.05.049]

44 Product information on Viekirax. [cited 4 October 2022]. Available from: https://www.ema.europa.eu/en/documents/product-information/viekirax-epar-product-information\_en.pdf

45 **Feld JJ**, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. *N Engl J Med* 2014; **370**: 1594-1603 [PMID: 24720703 DOI: 10.1056/NEJMoa1315722]

46 **Zeuzem S**, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. *N Engl J Med* 2014; **370**: 1604-1614 [PMID: 24720679 DOI: 10.1056/NEJMoa1401561]

47 **Ferenci P**, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. *N Engl J Med* 2014; **370**: 1983-1992 [PMID: 24795200 DOI: 10.1056/NEJMoa1402338]

48 **Welzel TM**, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, Forns X, Pilot-Matias T, Lu W, Cohen DE, Feld JJ. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. *Lancet Gastroenterol Hepatol* 2017; **2**: 494-500 [PMID: 28416221 DOI: 10.1016/S2468-1253(17)30071-7]

49 **Asselah T**, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. *Lancet Gastroenterol Hepatol* 2016; **1**: 25-35 [PMID: 28404108 DOI: 10.1016/S2468-1253(16)30001-2]

50 **Asselah T**, Alami NN, Moreno C, Pol S, Karatapanis S, Gschwantler M, Horsmans Y, Elefsiniotis I, Larrey D, Ferrari C, Rizzetto M, Orlandini A, Calleja JL, Bruno S, Schnell G, Qaqish R, Redman R, Pilot-Matias T, Kopecky-Bromberg S, Yu Y, Mobashery N. Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II). *Health Sci Rep* 2019; **2**: e92 [PMID: 30937389 DOI: 10.1002/hsr2.92]

51 **Waked I**, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, Soliman R, Mohey MA, Allam N, Zayed N, Asselah T, Hall C, Redman R, Mobashery N, Doss W. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. *Lancet Gastroenterol Hepatol* 2016; **1**: 36-44 [PMID: 28404110 DOI: 10.1016/S2468-1253(16)30002-4]

52 **Flisiak R**, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarębska-Michaluk D, Nazzal K, Bolewska B, Bialkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Rostkowska K, Piekarska A, Tronina O, Madej G, Garlicki A, Lucejko M, Pisula A, Karpińska E, Kryczka W, Wiercińska-Drapało A, Mozer-Lisewska I, Jabłkowski M, Horban A, Knysz B, Tudrujek M, Halota W, Simon K. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. *Aliment Pharmacol Ther* 2016; **44**: 946-956 [PMID: 27611776 DOI: 10.1111/apt.13790]

53 **Welzel TM**, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van Bömmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, König B, Hüppe D, Wedemeyer H. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. *J Viral Hepat* 2017; **24**: 840-849 [PMID: 28342229 DOI: 10.1111/jvh.12708]

54 **Ferenci P**, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. *J Viral Hepat* 2019; **26**: 685-696 [PMID: 30739368 DOI: 10.1111/jvh.13080]

55 **Backus LI**, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. *Aliment Pharmacol Ther* 2016; **44**: 400-410 [PMID: 27291852 DOI: 10.1111/apt.13696]

56 **Zarębska-Michaluk D**, Piekarska A, Jaroszewicz J, Klapaczyński J, Mazur W, Krygier R, Belica-Wdowik T, Baka-Ćwierz B, Janczewska E, Pabjan P, Dobracka B, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Czauż-Andrzejuk A, Citko J, Dybowska D, Halota W, Pawłowska M, Laurans Ł, Deroń Z, Buczyńska I, Simon K, Białkowska J, Tronina O, Flisiak R. Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. *Adv Med Sci* 2020; **65**: 12-17 [PMID: 31841821 DOI: 10.1016/j.advms.2019.09.002]

57 **Manuc M,** Preda CM, Iliescu L, Istratescu D, Chifulescu AE, Pop CS, Trifan A, Stanciu C, Popescu CP, Diculescu M-M, Manuc T, Tugui L, Cianga E, Tieranu CG, Stroie T, Gheorghe LS. Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 vs 12 wk in chronic HCV hepatitis genotype 1b. *Rom J Infect Dis* 2021; **24**: 44-50 [DOI: 10.37897/RJID.2021.1.6]

58 **Zeuzem S**, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. *Ann Intern Med* 2015; **163**: 1-13 [PMID: 25909356 DOI: 10.7326/M15-0785]

59 **Kwo P**, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. *Gastroenterology* 2017; **152**: 164-175.e4 [PMID: 27720838 DOI: 10.1053/j.gastro.2016.09.045]

60 **Lawitz E**, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med* 2013; **368**: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]

61 **Jacobson IM**, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med* 2013; **368**: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]

62 **Foster GR**, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM, Massetto B, Lin M, Han B, McHutchison JG, Subramanian GM, Cooper C, Agarwal K; BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. *Gastroenterology* 2015; **149**: 1462-1470 [PMID: 26248087 DOI: 10.1053/j.gastro.2015.07.043]

63 **Zarębska-Michaluk D**, Flisiak R, Jaroszewicz J, Janczewska E, Czauż-Andrzejuk A, Berak H, Horban A, Staniaszek A, Gietka A, Tudrujek M, Tomasiewicz K, Dybowska D, Halota W, Piekarska A, Sitko M, Garlicki A, Orłowska I, Simon K, Belica-Wdowik T, Baka-Ćwierz B, Mazur W, Białkowska J, Socha Ł, Wawrzynowicz-Syczewska M, Laurans Ł, Deroń Z, Lorenc B, Dobracka B, Tronina O, Pawłowska M. Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? *J Interferon Cytokine Res* 2018; **38**: 93-100 [PMID: 29443655 DOI: 10.1089/jir.2017.0113]

64 **Backus LI**, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. *Aliment Pharmacol Ther* 2015; **42**: 559-573 [PMID: 26113432 DOI: 10.1111/apt.13300]

65 **Nelson DR**, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. *Hepatology* 2015; **61**: 1127-1135 [PMID: 25614962 DOI: 10.1002/hep.27726]

66 FDA approves Epclusa for treatment of chronic Hepatitis C. 2016 Jun 28 [cited 4 October 2022]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-epclusa-treatment-chronic-hepatitis-c-virus-infection

67 **Feld JJ**, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. *N Engl J Med* 2015; **373**: 2599-2607 [PMID: 26571066 DOI: 10.1056/NEJMoa1512610]

68 **Foster GR**, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. *N Engl J Med* 2015; **373**: 2608-2617 [PMID: 26575258 DOI: 10.1056/NEJMoa1512612]

69 **Curry MP**, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M; ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *N Engl J Med* 2015; **373**: 2618-2628 [PMID: 26569658 DOI: 10.1056/NEJMoa1512614]

70 **Mangia A**, Milligan S, Khalili M, Fagiuoli S, Shafran SD, Carrat F, Ouzan D, Papatheodoridis G, Ramji A, Borgia SM, Wedemeyer H, Losappio R, Pérez-Hernandez F, Wick N, Brown RS Jr, Lampertico P, Doucette K, Ntalla I, Ramroth H, Mertens M, Vanstraelen K, Turnes J. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. *Liver Int* 2020; **40**: 1841-1852 [PMID: 32449966 DOI: 10.1111/liv.14537]

71 FDA approves Mavyret for treatment of Hepatitis C. 2017 Aug 03 [cited 4 October 2022]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-mavyret-hepatitis-c

72 **Zeuzem S**, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. *N Engl J Med*2018; **378**: 354-369 [PMID: 29365309 DOI: 10.1056/NEJMoa1702417]

73 **Forns X**, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. *Lancet Infect Dis* 2017; **17**: 1062-1068 [PMID: 28818546 DOI: 10.1016/S1473-3099(17)30496-6]

74 **Asselah T**, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. *Clin Gastroenterol Hepatol* 2018; **16**: 417-426 [PMID: 28951228 DOI: 10.1016/j.cgh.2017.09.027]

75 **Kwo PY**, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. *J Hepatol* 2017; **67**: 263-271 [PMID: 28412293 DOI: 10.1016/j.jhep.2017.03.039]

76 **Brown RS Jr**, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-Perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin CW, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. *J Hepatol* 2020; **72**: 441-449 [PMID: 31682879 DOI: 10.1016/j.jhep.2019.10.020]

77 **Madsen LW**, Christensen PB, Fahnøe U, Pedersen MS, Bukh J, Øvrehus A. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C. *Liver Int* 2021; **41**: 2601-2610 [PMID: 34154034 DOI: 10.1111/liv.14991]

78 **Gane E**, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida EM, Nelson DR, Collins C, Lei Y, Kosloski M, Mensa FJ. Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. *N Engl J Med* 2017; **377**: 1448-1455 [PMID: 29020583 DOI: 10.1056/NEJMoa1704053]

79 **Lampertico P**, Carrión JA, Curry M, Turnes J, Cornberg M, Negro F, Brown A, Persico M, Wick N, Porcalla A, Pangerl A, Crown E, Larsen L, Yu Y, Wedemeyer H. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. *J Hepatol* 2020; **72**: 1112-1121 [PMID: 32061651 DOI: 10.1016/j.jhep.2020.01.025]

80 FDA approves Vosevi for re-treatment of chronic Hepatitis C. 2017 Jul 18 [cited 4 October 2022]. Available from: https://www.drugs.com/newdrugs/fda-approves-vosevi-sofosbuvir-velpatasvir-voxilaprevir-re-adults-chronic-hepatitis-c-virus-4562.html

81 **Zeuzem S**, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. *N Engl J Med* 2014; **370**: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]

82 **Omata M**, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, Ishizaki A, Omote M, Brainard D, Knox S, Symonds WT, McHutchison JG, Yatsuhashi H, Mizokami M. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. *J Viral Hepat* 2014; **21**: 762-768 [PMID: 25196837 DOI: 10.1111/jvh.12312]

83 **Satsangi S**, Mehta M, Duseja A, Taneja S, Dhiman RK, Chawla Y. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C. *J Gastroenterol Hepatol* 2017; **32**: 859-863 [PMID: 27624314 DOI: 10.1111/jgh.13595]

84 **Bourlière M**, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. *N Engl J Med* 2017; **376**: 2134-2146 [PMID: 28564569 DOI: 10.1056/NEJMoa1613512]

85 World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. [cited 4 October 2022]. Available from: https://apps.who.int/iris/handle/10665/246177

86 World Health Organization. Interim guidance for country validation of viral hepatitis elimination. [cited 4 October 2022]. Available from: https://www.who.int/publications/i/item/9789240028395

87 **Polaris Observatory HCV Collaborators**. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. *Lancet Gastroenterol Hepatol* 2022; **7**: 396-415 [PMID: 35180382 DOI: 10.1016/S2468-1253(21)00472-6]

88 **Elsharkawy A**, El-Raziky M, El-Akel W, El-Saeed K, Eletreby R, Hassany M, El-Sayed MH, Kabil K, Ismail SA, El-Serafy M, Abdelaziz AO, Shaker MK, Yosry A, Doss W, El-Shazly Y, Esmat G, Waked I. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. *J Hepatol* 2018; **68**: 691-698 [PMID: 29223371 DOI: 10.1016/j.jhep.2017.11.034]

89 **Flisiak R**, Zarębska-Michaluk D, Jaroszewicz J, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Janczewska E, Pabjan P, Dybowska D, Buczyńska I, Czauż-Andrzejuk A, Belica-Wdowik T, Berak H, Krygier R, Piasecki M, Dobracka B, Citko J, Piekarska A, Socha Ł, Deroń Z, Tronina O, Laurans Ł, Białkowska J, Tomasiewicz K, Halota W, Simon K, Pawłowska M. Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection. *Pol Arch Intern Med* 2020; **130**: 163-172 [PMID: 32031541 DOI: 10.20452/pamw.15181]

90 **Reau N**, Sulkowski MS, Thomas E, Sundaram V, Xu Q, Cheng WH, Marx SE, Hayes OA, Manthena SR, Chirikov V, Dylla DE, Brooks H, Carabino JM, Saab S. Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. *Adv Ther* 2021; **38**: 5777-5790 [PMID: 34704194 DOI: 10.1007/s12325-021-01928-y]

91 **Hüppe D**, Serfert Y, Buggisch P, Mauss S, Böker KHW, Müller T, Klinker H, Günther R, Berg T, Cornberg M, Niederau C, Sarrazin C, Simon KG, Zeuzem S, Manns MP, Wedemeyer H. [4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]. *Z Gastroenterol* 2019; **57**: 27-36 [PMID: 30641600 DOI: 10.1055/a-0821-7188]

92 **Ministry of Health and Population**. Plan of Action for the Prevention, Care & Treatment of Viral Hepatitis, Egypt 2014–2018. 2014 Aug 03 [cited 4 October 2022]. Available from: http://www.emro.who.int/images/stories/egypt/VH\_Plan\_of\_Action\_FINAL\_PRINT1.pdf

93 **Polaris Observatory HCV Collaborators**. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. *Lancet Gastroenterol Hepatol* 2017; **2**: 161-176 [PMID: 28404132 DOI: 10.1016/S2468-1253(16)30181-9]

94 **European Association for the Study of the Liver**. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series(☆). *J Hepatol* 2020; **73**: 1170-1218 [PMID: 32956768 DOI: 10.1016/j.jhep.2020.08.018]

95 **Hüppe D**, Stoehr A, Buggisch P, Mauss S, Klinker H, Teuber G, Hidde D, Lohmann K, Bondin M, Wedemeyer H. The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). *J Viral Hepat* 2021; **28**: 1474-1483 [PMID: 34339561 DOI: 10.1111/jvh.13586]

96 **Yang J**, Liu HX, Su YY, Liang ZS, Rao HY. Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020. *World J Clin Cases* 2022; **10**: 4480-4493 [PMID: 35663077 DOI: 10.12998/wjcc.v10.i14.4480]

97 **Flisiak R**, Zarębska-Michaluk D, Ciupkeviciene E, Drazilova S, Frankova S, Grgurevic I, Hunyady B, Jarcuska P, Kupčinskas L, Makara M, Saulite-Vanaga G, Simonova M, Sperl J, Tolmane I, Vince A. HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons. *Viruses* 2022; **14** [PMID: 35336889 DOI: 10.3390/v14030482]

98 **Brzdęk M**, Dobrowolska K, Pabjan P, Zarębska-Michaluk D. Clinical characteristics and antiviral therapy in patients infected with hepatitis C virus in the interferon‑free era. *Pol Arch Intern Med* 2022; **132**: 16282 [PMID: 35938950 DOI: 10.20452/pamw.16282]

99 **Platt L**, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, Razavi H, Vickerman P. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. *Lancet Infect Dis* 2016; **16**: 797-808 [PMID: 26922272 DOI: 10.1016/S1473-3099(15)00485-5]

100 **Sulkowski MS**, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. *J Viral Hepat* 2007; **14**: 371-386 [PMID: 17501757 DOI: 10.1111/j.1365-2893.2006.00816.x]

101 **Rockstroh JK**, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. *Clin Infect Dis* 2018; **67**: 1010-1017 [PMID: 29566246 DOI: 10.1093/cid/ciy220]

102 **Rockstroh JK**, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. *Open Forum Infect Dis* 2017; **4**: ofx154 [PMID: 28948180 DOI: 10.1093/ofid/ofx154]

103 **Naggie S**, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. *N Engl J Med* 2015; **373**: 705-713 [PMID: 26196665 DOI: 10.1056/NEJMoa1501315]

104 **Wyles D**, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M; ASTRAL-5 Investigators. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. *Clin Infect Dis* 2017; **65**: 6-12 [PMID: 28369210 DOI: 10.1093/cid/cix260]

105 **Bischoff J**, Mauss S, Cordes C, Lutz T, Scholten S, Moll A, Jäger H, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? *HIV Med* 2018; **19**: 299-307 [PMID: 29368456 DOI: 10.1111/hiv.12579]

106 **Zarębska-Michaluk D**, Jaroszewicz J, Parfieniuk-Kowerda A, Pawłowska M, Janczewska E, Berak H, Janocha-Litwin J, Klapaczyński J, Tomasiewicz K, Piekarska A, Krygier R, Citko J, Tronina O, Dobrowolska K, Flisiak R. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection. *J Clin Med* 2022; **11**: 389 [PMID: 35054088 DOI: 10.3390/jcm11020389]

107 **Piekarska A**, Jabłonowska E, Garlicki A, Sitko M, Mazur W, Jaroszewicz J, Czauz-Andrzejuk A, Buczyńska I, Simon K, Lorenc B, Dybowska D, Halota W, Pawłowska M, Dobracka B, Berak H, Horban A, Tudrujek-Zdunek M, Tomasiewicz K, Janczewska E, Socha Ł, Laurans Ł, Parczewski M, Zarębska-Michaluk D, Pabjan P, Belica-Wdowik T, Baka-Ćwierz B, Deroń Z, Krygier R, Klapaczyński J, Citko J, Berkan-Kawińska A, Flisiak R. Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study. *AIDS Care* 2020; **32**: 762-769 [PMID: 31345052 DOI: 10.1080/09540121.2019.1645808]

108 **Milazzo L**, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, Ridolfo AL, Gervasoni C, Galli M, Antinori S, Sollima S. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. *HIV Med* 2017; **18**: 284-291 [PMID: 27477612 DOI: 10.1111/hiv.12429]

109 **Collins LF**, Chan A, Zheng J, Chow SC, Wilder JM, Muir AJ, Naggie S. Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection. *Open Forum Infect Dis* 2018; **5**: ofx264 [PMID: 29308413 DOI: 10.1093/ofid/ofx264]

110 **Pabjan P**, Brzdęk M, Chrapek M, Dziedzic K, Dobrowolska K, Paluch K, Garbat A, Błoniarczyk P, Reczko K, Stępień P, Zarębska-Michaluk D. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals? *Viruses* 2022; **14**: 96 [PMID: 35062302 DOI: 10.3390/v14010096]

111 **Schmitt A**, Günther R, Mauss S, Boeker KHW, Buggisch P, Hillenbrand H, John C, Klinker H, Pathil A, Simon KG, Serfert Y, Niederau C, Vermehren J, Wedemeyer H, Sarrazin C. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R). *Z Gastroenterol* 2020; **58**: 341-351 [PMID: 32040979 DOI: 10.1055/a-1068-3056]

112 **Zarębska-Michaluk D**, Buczyńska I, Simon K, Tudrujek-Zdunek M, Janczewska E, Dybowska D, Sitko M, Dobracka B, Jaroszewicz J, Pabjan P, Klapaczyński J, Laurans Ł, Mazur W, Socha Ł, Tronina O, Parczewski M, Flisiak R. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. *Can J Gastroenterol Hepatol* 2019; **2019**: 4029541 [PMID: 30941326 DOI: 10.1155/2019/4029541]

113 **Jaroszewicz J**, Zarębska-Michaluk D, Janocha-Litwin J, Parfieniuk-Kowerda A, Sitko M, Piekarska A, Białkowska J, Dybowska D, Murawska-Ochab A, Flisiak R. Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies. *Pol Arch Intern Med* 2023; Epub ahead of print [PMID: 36602060 DOI: 10.20452/pamw.16400]

114 **Corouge M**, Vallet-Pichard A, Pol S. HCV and the kidney. *Liver Int* 2016; **36 Suppl 1**: 28-33 [PMID: 26725894 DOI: 10.1111/liv.13022]

115 KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease - PMC. [cited 4 October 2022]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336217/

116 **Izzedine H**, Launay-Vacher V, Bourry E, Brocheriou I, Karie S, Deray G. Drug-induced glomerulopathies. *Expert Opin Drug Saf* 2006; **5**: 95-106 [PMID: 16370959 DOI: 10.1517/14740338.5.1.95]

117 **Fabrizi F**, Dixit V, Messa P, Martin P. Pegylated Interferon Mono-Therapy of Chronic Hepatitis C in the Dialysis Population: Systematic Review and Meta-Analysis. *Ther Apher Dial* 2015; **19**: 611-621 [PMID: 26197927 DOI: 10.1111/1744-9987.12318]

118 **Suda G**, Ogawa K, Kimura M, Nakai M, Sho T, Morikawa K, Sakamoto N. Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. *J Clin Transl Hepatol* 2016; **4**: 320-327 [PMID: 28097101 DOI: 10.14218/JCTH.2016.00032]

119 Product information on Sovaldi. [cited 4 October 2022]. Available from: https://www.ema.europa.eu/en/documents/product-information/sovaldi-epar-product-information\_en.pdf

120 HCV Guidelines for renal impairment. 2021 Sept 29 [cited 4 October 2022]. Available from: https://www.hcvguidelines.org/unique-populations/renal-impairment

121 **Li M**, Chen J, Fang Z, Li Y, Lin Q. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis. *Virol J* 2019; **16**: 34 [PMID: 30871566 DOI: 10.1186/s12985-019-1140-x]

122 **Saxena V**, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NA; HCV-TARGET. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. *Liver Int* 2016; **36**: 807-816 [PMID: 26923436 DOI: 10.1111/liv.13102]

123 Product information on Zepatier. [cited 4 October 2022]. Available from: https://www.ema.europa.eu/en/documents/product-information/zepatier-epar-product-information\_en.pdf

124 **Roth D**, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londoño MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. *Lancet* 2015; **386**: 1537-1545 [PMID: 26456905 DOI: 10.1016/S0140-6736(15)00349-9]

125 **Lawitz E**, Gane E, Cohen E, Vierling J, Agarwal K, Hassanein T, Mantry PS, Pockros PJ, Bennett M, Kemmer N, Morelli G, Zha J, Wang D, Shulman NS, Cohen DE, Reddy KR. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. *Kidney Int Rep* 2019; **4**: 257-266 [PMID: 30775622 DOI: 10.1016/j.ekir.2018.10.003]

126 **Lawitz E**, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, Bruchfeld A, Wörns MA, Aglitti A, Zamor PJ, Xue Z, Schnell G, Jalundhwala YJ, Porcalla A, Mensa FJ, Persico M. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. *Liver Int* 2020; **40**: 1032-1041 [PMID: 31821716 DOI: 10.1111/liv.14320]

127 **Ahmed H**, Abushouk AI, Menshawy A, Attia A, Mohamed A, Negida A, Abdel-Daim MM. Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection. *Ann Hepatol* 2018; **17**: 18-32 [PMID: 29311409 DOI: 10.5604/01.3001.0010.7532]

128 **Poordad F**, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. *N Engl J Med* 2014; **370**: 1973-1982 [PMID: 24725237 DOI: 10.1056/NEJMoa1402869]

129 **Gane E**, Poordad F, Zadeikis N, Valdes J, Lin CW, Liu W, Asatryan A, Wang S, Stedman C, Greenbloom S, Nguyen T, Elkhashab M, Wörns MA, Tran A, Mulkay JP, Setze C, Yu Y, Pilot-Matias T, Porcalla A, Mensa FJ. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease. *Clin Infect Dis* 2019; **69**: 1657-1664 [PMID: 30923816 DOI: 10.1093/cid/ciz022]

130 **Naguib GG**, Farid A, Hassan M, Elshafie A, Shazly YE, Shaker MK, Ezzat H, Safwat E, Ahmed OA, Dabbous H, Sherief AF, Hassany M, Elserafy M, Elsayed MH. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience. *Arab J Gastroenterol* 2021; **22**: 285-291 [PMID: 34531135 DOI: 10.1016/j.ajg.2021.06.001]

131 **Talal AH**, LaFleur J, Hoop R, Pandya P, Martin P, Jacobson I, Han J, Korner EJ. Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients. *Aliment Pharmacol Ther* 2013; **37**: 473-481 [PMID: 23289640 DOI: 10.1111/apt.12200]

132 Product information on Harvoni. [cited 4 October 2022]. Available from: https://www.ema.europa.eu/en/documents/product-information/harvoni-epar-product-information\_en.pdf

133 Product information on Epclusa. [cited 4 October 2022]. Available from: https://www.ema.europa.eu/en/documents/product-information/epclusa-epar-product-information\_en.pdf

134 Product information on Daklinza. [cited 4 October 2022]. Available from: https://www.ema.europa.eu/en/documents/product-information/daklinza-epar-product-information\_en.pdf

135 **Janczewska E**, Kołek MF, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Zarębska-Michaluk D, Buczyńska I, Dybowska D, Czauż-Andrzejuk A, Berak H, Krygier R, Jaroszewicz J, Citko J, Piekarska A, Dobracka B, Socha Ł, Deroń Z, Laurans Ł, Białkowska-Warzecha J, Tronina O, Adamek B, Tomasiewicz K, Simon K, Pawłowska M, Halota W, Flisiak R. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. *World J Gastroenterol* 2021; **27**: 2177-2192 [PMID: 34025072 DOI: 10.3748/wjg.v27.i18.2177]

136 **Soria A**, Fava M, Bernasconi DP, Lapadula G, Colella E, Valsecchi MG, Migliorino GM, D'Ambrosio R, Landonio S, Schiavini M, Spinetti A, Carriero C, Degasperi E, Cologni G, Gatti F, Viganò P, Hasson H, Uberti-Foppa C, Pasulo L, Baiguera C, Rossotti R, Vinci M, Puoti M, Giorgini A, Menzaghi B, Lombardi A, Pan A, Aghemo A, Grossi PA, Boldizzoni R, Colombo S, Viganò M, Rumi MG, Del Poggio P, Valenti L, Giglio O, De Bona A, d'Arminio Monforte A, Colombo A, Spinelli O, Pigozzi MG, Molteni C, Bonfanti P, Terreni N, Perini P, Capretti A, Bella D, Liani C, Polo S, Aimo G, Pagnucco L, Bhoori S, Centenaro R, Graffeo M, Ciaccio A, Dionigi E, Lazzaroni S, Carderi I, Di Marco M, Rizzardini G, Noventa F, Lampertico P, Fagiuoli S. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. *Liver Int* 2020; **40**: 769-777 [PMID: 31970845 DOI: 10.1111/liv.14386]

137 **Zarębska-Michaluk D**, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawłowska M, Halota W, Mazur W, Lorenc B, Janocha-Litwin J, Simon K, Piekarska A, Berak H, Klapaczyński J, Stępień P, Sobala-Szczygieł B, Citko J, Socha Ł, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Dobracka B, Krygier R, Białkowska-Warzecha J, Laurans Ł, Flisiak R. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. *J Clin Med* 2021; **10** [PMID: 34362064 DOI: 10.3390/jcm10153280]

138 **Naggie S**, Muir AJ. Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. *Annu Rev Med* 2017; **68**: 345-358 [PMID: 27686017 DOI: 10.1146/annurev-med-052915-015720]

139 **Sarrazin C**. Treatment failure with DAA therapy: Importance of resistance. *J Hepatol* 2021; **74**: 1472-1482 [PMID: 33716089 DOI: 10.1016/j.jhep.2021.03.004]

140 **Xie J**, Xu B, Wei L, Huang C, Liu W. Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis. *Infect Dis Ther* 2022; **11**: 1661-1682 [PMID: 35749010 DOI: 10.1007/s40121-022-00666-0]

141 **Llaneras J**, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carrión J, Fernández I, María Morillas R, Rosales JM, Carmona I, Fernández-Rodríguez C, Hernández-Guerra M, Llerena S, Bernal V, Turnes J, González-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fernández-Bermejo M, Iñarrairaegui M, Pascasio JM, Esteban R, Mariño Z, Buti M. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. *J Hepatol* 2019; **71**: 666-672 [PMID: 31203153 DOI: 10.1016/j.jhep.2019.06.002]

142 HCV Guidelines on treatment experienced patients. 2021 Jan 21 [cited 4 October 2022]. Available from: https://www.hcvguidelines.org/treatment-experienced

143 **Wyles D**, Weiland O, Yao B, Weilert F, Dufour JF, Gordon SC, Stoehr A, Brown A, Mauss S, Zhang Z, Pilot-Matias T, Rodrigues L Jr, Mensa FJ, Poordad F. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. *J Hepatol* 2019; **70**: 1019-1023 [PMID: 30857780 DOI: 10.1016/j.jhep.2019.01.031]

144 **Gane EJ,** Faire B, Helmy S, Freeman J. Glecaprevir/pibrentasvir & sofosbuvir for 16 wk without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen. Conference Reports for NATAP; The International Liver Congress™ EASL – European Association for the Study of the Liver. 2022 June 22-26 [cited 4 October 2022]. Available from: https://www.natap.org/2022/EASL/EASL\_48.htm

**Footnotes**

**Conflict-of-interest statement:** The authors declare having no relevant conflicts of interest within the submitted work.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 12, 2022

**First decision:** November 15, 2022

**Article in press:**

**Specialty type:** Virology

**Country/Territory of origin:** Poland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Lo SY, Taiwan; Sahin TT, Turkey **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:** Zhang H

**Figure Legends**

**Table 1 Efficacy of genotype-specific regimens in phase III of clinical trials**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Number of participants** | **Regimen** | **GT** | **SVR (mITT analysis) *n*/*N* (%)** | | | |
| **Patients without cirrhosis** | | **Patients with cirrhosis** | |
| **Treatment-naïve** | **Treatment-experienced** | **Treatment-naïve** | **Treatment-experienced** |
| Afdhal *et al*[40] (ION-1) | 865 | LDV/SOF, 12 wk (*n* = 214) | 1 | 179/179 (100) |  | 32/33 (97.0) |  |
| LDV/SOF + RBV, 12 wk (*n* = 217) | 178/178 (100) | 33/33 (100) |
| LDV/SOF, 24 wk, (*n* = 217) | 181/182 (99.5) | 31/32 (96.9) |
| LDV/SOF + RBV, 24 wk (*n* = 217) | 179/179 (100) | 36/36 (100) |
| Afdhal *et al*[41] (ION-2) | 440 | LDV/SOF, 12 wk (*n* = 109) | 1 |  | 83/87 (95.4) |  | 19/22 (86.4) |
| LDV/SOF + RBV, 12 wk (*n* = 111) | 89/89 (100) | 18/22 (81.8) |
| LDV/SOF, 24 wk, (*n* = 109) | 86/87 (98.9) | 22/22 (100) |
| LDV/SOF + RBV, 24 wk (*n* = 111) | 88/89 (98.9) | 22/22 (100) |
| Kowdley *et al*[42] (ION-3) | 647 | LDV/SOF, 8 wk (*n* = 215) | 1 | 202/214 (94.4) |  |  |  |
| LDV/SOF + RBV, 8 wk (*n* = 216) | 201/211 (95.3) |
| LDV/SOF, 12 wk (*n* = 216) | 206/209 (98.6) |
| Feld *et al*[45] (SAPPHIRE-I) | 473 | OBV/PTV/r + DSV + RBV, 12 wk | 1 | 455/473 (96.2) |  |  |  |
| Zeuzem *et al*[46] (SAPPHIRE-II) | 297 | OBV/PTV/r + DSV + RBV, 12 wk | 1 |  | 286/297 (96.3) |  |  |
| Ferenci *et al*[47] (PEARL-III) | 419 | OBV/PTV/r + DSV + RBV, 12 wk (*n* = 210) | 1b | 209/210 (99.5) |  |  |  |
|  |  | OBV/PTV/r + DSV + placebo, 12 wk (*n* = 209) |  | 207/207 (100) |  |  |  |
| Ferenci *et al*[47] (PEARL-IV) | 305 | OBV/PTV/r + DSV + RBV, 12 wk (*n* = 100) | 1a | 97/99 (98.0) |  |  |  |
|  |  | OBV/PTV/r + DSV + placebo, 12 wk (*n* = 205) |  | 185/204 (90.7) |  |  |  |
| Welzel *et al*[48] (GARNET) | 163 | OBV/PTV/r + DSV, 8 wk | 1b | 160/162 (99.0) |  |  |  |
| Asselah *et al*[49] (AGATE-I) | 120 | OBV/PTV/r + RBV, 12 wk (*n* = 59) | 4 |  | - | 57/58 (98.0) |  |
|  |  | OBV/PTV/r + RBV, 16 wk (*n* = 61) |  |  |  | 60/60 (100) |  |
| Asselah *et al*[50] (AGATE-I Part II) | 64 | OBV/PTV/r + RBV, 24 wk | 4 |  |  | 60/60 (100) |  |
| Waked *et al*[51] (AGATE-II) | 160 | OBV/PTV/r + RBV, 12 wk (*n* = 131) | 4 | 94/98 (96.0) | 30/31 (97.0) |  |  |
|  |  | OBV/PTV/r + RBV, 24 wk (*n* = 29) |  |  |  | 27/28 (96.0) |  |
| Zeuzem *et al*[58] (C-EDGE treatment naïve) | 421 | GZR/EBR ± RBV, 12 wk | 1, 4, 6 | 68/70 (97.0)1 |  | 231/246 (94.0)1 |  |
| Kwo *et al*[59] (C-EDGE treatment-experienced) | 420 | GZR/EBR ± RBV, 12 or 16 wk | 1, 4, 6 |  | 255/264 (96.6) |  | 135/144 (93.8) |

1Intent-to-treat analysis (no data for modified intent-to-treat analysis). DSV: Dasabuvir; EBR: Elbasvir; GT: Genotype; GZR: Grazoprevir; LDV: Ledipasvir; mITT: Modified intention-to-treat; OBV: Ombitasvir; PTV/r: Paritaprevir; RBV: Ribavirin; SOF: Sofosbuvir; SVR: Sustained virological response.

**Table 2 Efficacy of pangenotypic regimens in phase III of clinical trials**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Number of participants** | **Regimen** | **GT** | **SVR (mITT analysis) *n*/*N* (%)** | | | |
| **Patients without cirrhosis** | | **Patients with cirrhosis** | |
| **Treatment-naïve** | **Treatment-experienced** | **Treatment-naïve** | **Treatment-experienced** |
| Lawitz *et al*[60] (FISSION) | 256 | SOF + RBV, 12 wk | 1-3 | 147/204 (72.1) |  | 23/49 (46.9) |  |
| Jacobson *et al*[61] (FUSION) | 201 | SOF + RBV, 12 wk (*n* = 103) | 2, 3 |  | 25/26 (96.2), 14/38 (36.8) |  | 6/10 (60.0), 5/26 (19.2) |
| SOF + RBV, 16 wk (*n* = 98) | 2, 3 | 23/23 (100), 25/40 (62.5) | 7/9 (77.8), 14/23 (60.9) |
| Jacobson *et al*[61] (POSITION) | 207 | SOF + RBV, 12 wk | 2 |  | 85/92 (92.0%) |  | 16/17 (94.0%) |
| 3 |  | 57/84 (68.0%) |  | 3/14 (21.0%) |
| Zeuzem *et al*[81] (VALENCE)1 | 323 | SOF + RBV, 12 wk (*n* = 73) | 2 | 29/30 (96.7) | 30/32 (93.8) | 2/2 (100) | 7/9 (77.8) |
| SOF + RBV, 24 wk (*n* = 250) | 3 | 87/92 (94.6) | 85/98 (86.7) | 12/13 (92.3) | 29/47 (61.7) |
| Omata *et al*[82] | 153 | SOF + RBV, 12 wk | 2 | 80/82 (95.0) | 52/54 (100) | 8/8 (100) | 8/9 (89.0) |
| Foster *et al*[62] (BOSON)1 | 363 | SOF + RBV, 16 wk | 3 | 58/70 (83.0) | 41/54 (76.0) | 12/21 (57.0) | 17/36 (47.0) |
| SOF + RBV, 24 wk | 65/72 (90.0) | 44/54 (81.0) | 18/22 (82.0) | 26/34 (76.0) |
| Satsangi *et al*[83] | 105 | SOF + RBV, 24 wk | 3 | 49/49 (100) | 1/1 (100) | 22/23 (95.6) | 3/3 (100) |
| Nelson *et al*[65] (ALLY-3) | 152 | DCV + SOF, 12 wk | 3 | 105/109 (96.0) | | 20/32 (63.0) | |
| 73/75 (97.0) | 32/34 (94.0) | 11/19 (58.0) | 9/13 (69.0) |
| Feld *et al*[67] (ASTRAL-1) | 624 | SOF/VEL, 12 wk | 1, 2, 4, 5, 6 | 496/501 (99.0) | | 120/121 (99.2) | |
|  |  |  |  |
| Foster *et al*[68] (ASTRAL-2) | 266 | SOF/VEL, 12 wk (*n* = 134) | 2 | 133/134 (99.0) | | | |
| SOF + RBV, 12 wk (*n* = 132) | 124/132 (94.0) | | | |
| Foster *et al*[68] (ASTRAL-3) | 552 | SOF/VEL, 12 wk (*n* = 277) | 3 | 160/163 (98.0) | 31/34 (91.0) | 40/43 (93.0) | 33/37 (89.0) |
| SOF + RBV, 24 wk (*n* = 275) | 141/156 (90.0) | 22/31 (71.0) | 33/45 (73.0) | 22/38 (58.0) |
| Curry *et al*[69] (ASTRAL-4) | 267 | SOF/VEL, 12 wk (*n* = 90) | 1-6 |  |  | 75/89 (84.3) | |
| SOF/VEL + RBV 12 wk (*n* = 87) | 82/87 (94.0) | |
| SOF/VEL, 24 wk (*n* = 90) | 77/87 (88.5) | |
| Forns *et al*[73] (EXPEDITION-1) | 146 | GLE/PIB, 12 wk | 1, 2, 4, 5 or 6 |  |  | 145/146 (99.0) | |
| Zeuzem *et al*[81] (ENDURANCE-1) | 703 | GLE/PIB, 8 wk (*n* = 351) | 1 | 343/344 (99.7) | |  |  |
| GLE/PIB, 12 wk (*n* = 352) | 345/345 (100) | |
| Zeuzem *et al*[72] (ENDURANCE-3) | 505 | GLE/PIB, 12 wk (*n* = 233) | 3 | 214/217 (99.0) | |  |  |
| SOF + DCV, 12 wk (*n* = 115) | 110/111 (99.0) | |
| GLE/PIB, 8 wk (*n* = 157) | 143/149 (96.0) | |
| Asselah *et al*[74] (ENDURANCE-2) | 202 | GLE/PIB, 12 wk | 2 | 192/192 (100) | |  |  |
| Asselah *et al*[74] (ENDURANCE-4) | 121 | GLE/PIB, 12 wk | 4-6 | 120/120 (100) | |  |  |
| Brown *et al*[76] (EXPEDITION-8) | 343 | GLE/PIB, 8 wk | 1-6 |  |  | 334/335 (99.7) |  |
| Gane *et al*[78] (EXPEDITION-4) | 104 | GLE/PIB, 12 wk | 1-6 | 102/104 (98.0) | | | |
| Bourlière *et al*[84] (POLARIS-1)1 | 263 | SOF/VEL/VOX, 12 wk | 1-6 | 253/263 (96.0)2 | | | |
| Bourlière *et al*[84] (POLARIS-4)1 | 182 | SOF/VEL/VOX, 12 wk | 1-4 | 178/182 (98.0)2 | | | |

1Intent-to-treat analysis (no data for modified intent-to-treat analysis). 2All analyzed patients were previously treated with a direct-acting antiviral-containing regimen. DCV: Daclatasvir; GLE: Glecaprevir; GT: Genotype; mITT: Modified intention-to-treat; PIB: Pibrentasvir; RBV: Ribavirin; SOF: Sofosbuvir; SVR: Sustained virological response; VEL: Velpatasvir; VOX: Voxilaprevir.